Revelation Biosciences Reveals Encouraging Preclinical Data From Its Lead Fibrosis Candidate

Revelation Biosciences Inc REVB announced biomarker data from a preclinical model of acute and chronic kidney disease, supporting the potential clinical utility of REVTx-300 previously announced in November last year.
In this validated preclinical model, administration of REVTx-300 caused a significant reduction in circulating transforming growth factor-β (TGF-β) in a dose-dependent manner relative to the positive control group.
In addition, REVTx-300 significantly increased circulating anti-inflammatory interleukin-10, hepcidin, and neutrophil gelatinase-associated lipocalin in all groups in a dose-dependent manner relative to the positive control group.
There were no significant increases in markers of inflammation. Revelation plans to seek publication of the full results during 2023.
Revelation originally released positive results from the preclinical model of acute kidney injury and chronic kidney disease.
Additional analysis found that treatment with REVTx-300 significantly reduced new collagen deposition (fibrosis) in the renal cortex in a dose-dependent manner in the medium and high dose groups (42.1% reduction and 56.7%, respectively).
Price Action: REVB shares are up 0.72% at $8.66 on the last check Tuesday.